Back to All
Group

Webinar: How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights

22 September, 2016

To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized. Listen to the webinar to learn:

  • 10 years of personalized medicine evidence-based insights from Diaceutics
  • The latest in data and research on PD-L1 testing, adoptions, kits and labels
  • How to prepare for targeted therapy launches
  • Laboratory mapping and optimal lab footprints based on therapy, test and target prescribers

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny